| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Leucine-rich repeats and immunoglobulin-like domains protein 2, LIG-2, LRIG2, KIAA0806, LIG2 |
| Entrez GeneID | 9860 |
| WB Predicted band size | 119.0kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This LRIG2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 817-845 amino acids from the C-terminal region of human LRIG2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于LRIG2抗体的模拟参考文献示例(实际文献需通过学术数据库查询)：
1. **标题**: *LRIG2 Antibody Characterization and Expression in Human Tissues*
**作者**: Suzuki K, et al.
**摘要**: 研究开发了特异性识别LRIG2蛋白的多克隆抗体，并通过免疫组化验证其在正常和肿瘤组织中的差异表达，提示LRIG2可能参与细胞增殖调控。
2. **标题**: *LRIG2 as a Prognostic Marker in Gliomas: Immunohistochemical Analysis*
**作者**: Holmlund C, et al.
**摘要**: 利用LRIG2抗体分析胶质瘤样本，发现LRIG2高表达与患者生存率正相关，表明其可能通过抑制EGFR信号通路发挥抑癌作用。
3. **标题**: *Role of LRIG2 in Neuronal Development: Evidence from Knockout Mice*
**作者**: Afzal S, Wong JC.
**摘要**: 通过LRIG2抗体免疫荧光定位，发现LRIG2在小鼠大脑皮层发育中表达，敲除后导致神经元迁移异常，提示其对神经系统发育至关重要。
4. **标题**: *LRIG2 Interaction with EGFR: Antibody-Mediated Blockade Studies*
**作者**: Zhang Y, et al.
**摘要**: 研究使用LRIG2抗体阻断其与EGFR的结合，证实LRIG2通过负向调控EGFR信号影响癌细胞侵袭能力，为靶向治疗提供依据。
**建议**：以上为模拟示例，实际文献请通过PubMed、Google Scholar等平台搜索“LRIG2 antibody”或“LRIG2 immunohistochemistry”获取，并关注近五年研究以确保时效性。
The LRIG2 (Leucine-rich Repeats and Immunoglobulin-like Domains 2) antibody is a research tool designed to detect and study the LRIG2 protein, a member of the LRIG family of transmembrane proteins. LRIG2 plays a regulatory role in cellular signaling pathways, particularly through interactions with receptor tyrosine kinases such as EGFR (epidermal growth factor receptor). It is implicated in modulating cell proliferation, differentiation, and apoptosis, with emerging roles in cancer biology and neurological disorders. Aberrant LRIG2 expression has been observed in certain cancers (e.g., gliomas, cervical cancer) and neurological conditions like hydrocephalus, suggesting its potential as a biomarker or therapeutic target.
LRIG2 antibodies are typically monoclonal or polyclonal, developed against specific epitopes of the protein. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess protein expression, localization, and interactions in tissues or cell lines. Researchers also utilize these antibodies to explore LRIG2’s functional mechanisms, such as its role in modulating oncogenic signaling or maintaining neural homeostasis. Despite progress, the full scope of LRIG2’s biological functions and clinical relevance remains under investigation, driving ongoing demand for high-specificity antibodies to advance mechanistic and translational studies.
×
